Keywords: AstraZeneca, Targacept, TC-5214, Depressive disorder, Market

AstraZeneca/Targacept's TC-5214 to be DR’s clinical “Gold Standard” In 2013

Article | 20 April 2010

Anglo-Swedish drug major AstraZeneca and partner Targacept's TC-5214 will earn Decision Resources' proprietary clinical “gold standard” status in 2013 (following its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

AstraZeneca

Targacept

Go to company listing